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Abstract
Here we define precision medicine approaches and discuss how these may be applied to renal stone-formers to optimise 
diagnosis and a management. Using the gene discovery of monogenic stone disorders as examples, we discuss the benefits 
of personalising therapies for renal stone-formers to provide improved prevention and treatment of these disorders.
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Introduction
Renal stones, amongst the lay population, are infamous for 
their ability to cause severe agonising pain. With 1–5% of 
the world’s population estimated to develop nephrolithiasis 
at some point in their life [33], many people will recognise 
the cardinal symptoms of colic secondary to renal stone dis-
ease. The search to uncover genetic (usually within single 
genes) and genomic factors (within a person’s entire set of 
DNA sequence) predisposing to renal stone formation has 
been a more complex and often less commonly explored 
path [27, 28].
In order to discuss how a “precision medicine” (or some-
times referred to as a “personalised medicine”) approach 
may help the identification and management of stone-
formers, it is worth considering its definition. NHS Eng-
land defines personalised medicine as a “move away from 
a ‘one size fits all’ approach to the treatment and care of 
patients with a particular condition, to one which uses new 
approaches to better manage patients’ health and targets 
therapies to achieve the best outcomes in the management 
of a patient’s disease or predisposition to disease.” (https ://
www.engla nd.nhs.uk/healt hcare -scien ce/perso nalis edmed 
icine /). Similarly, the NIH describe “precision medicine” as 
an approach for disease treatment and prevention that takes 
into account individual variability in genes, environment, 
and lifestyle for each person. Thus, this general view can 
be adopted to include the utilisation of both modern day 
investigations and more traditional approaches to understand 
more precisely and tailor the treatment of renal stone disease 
on an individual or patient by patient level. The combina-
tion of genetic and genomic information with other clinical 
and biochemical parameters will allow patterns of risk and 
disease susceptibility to be identified which should lead to 
earlier detection of illness and more effective interventions.
Furthermore, when considering genomic influence on 
disease, it is now imperative that we consider both the influ-
ences of the host genome, i.e. that of the patient as well as 
the host microbiome [22], the multitudes of microbes which 
colonise the body of the host. Within this microbiome, the 
number of bacterial cells is more than tenfold greater than 
the number of hosts cells [4]. Approaches to manipulate this 
distinctly separate but intimately related genome are being 
applied to kidney stone-formers and must be included in 
discussions relating to precision medicine approaches.
Traditional approaches to renal stone formation have 
typically considered environmental, geographic and dietary 
factors which might predispose to stone formation [33] and 
are often based on population studies. In addition, the herit-
ability of renal stones has also been long established. Using 
twin studies, the estimated heritability of kidney stones was 
56% [9], and this has been backed up by other studies assess-
ing the familial pattern of stones [5, 17]. More recently, there 
has been the detailed search for rare monogenetic causes of 
renal stones using selected stone-forming populations [3, 
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6, 12]. Whilst rare monogenic forms of stone disease might 
initially appear a fine-print issue, to be reserved for the spe-
cialist, missed diagnoses of monogenetic causes of neph-
rolithiasis can lead to sub-optimal treatment, development 
of complications, including progression to end-stage renal 
disease, and failure to screen at risk family members [7].
Testing for known pathogenic mutations through high-
throughput genetic analysis (such a gene panels and whole 
exome sequencing that modern next-generation sequenc-
ing techniques allow), is rapidly becoming an accessible 
diagnostic tool [3, 12]. The question remains whether this 
approach is worthwhile and fruitful in general calcium-
forming stone populations. Indeed, in studies of hypercal-
ciuric and hypocalciuric patients monogenic causes and rare 
alleles were not readily identified [32]. CLCN5 variants were 
a plausible cause of idiopathic hypercalciuria but found to be 
rare [29]. Therefore, when considering performing genetic 
investigations on renal stone-formers, there is a balance 
of being able to discover a small yet significant number 
of monogenetic conditions (Table 1) versus the cost and 
resources that are required for such investigations. It could 
be argued that it is only when we obtain molecular precision 
in our diagnosis that we can expect to achieve accurate, per-
sonalised treatment for the patient. For the small number of 
patients with a monogenetic cause of their nephrolithiasis, a 
correct diagnosis may be crucial. Such monogenic disorders 
are likely to lead to increasing stone burdens and chronic 
kidney disease. Lack of genetic investigations may lead to 
delays in diagnosis, unscreened at risk family members [3, 
12]. It is important to note that monogenic causes of stone, 
for example cystinuria, often produce recurrent stones, may 
present early in life and often lead to long-term serious com-
plications, including end-stage renal disease [24].
Spotting the genetic cases of renal stone 
disease: the diagnoses not to miss
The immediate priority for the physician treating the patient 
presenting with renal colic is to confirm the clinical diag-
nosis, alleviate pain and treat the presenting problem. The 
underlying causes and predisposing factors may not be at the 
forefront of considerations at this stage, and even with recur-
rent stone-formers, may be repeatedly neglected. Success-
fully delivering a personalised approach to stone-formers 
starts, in our opinion, with stone analysis, then proceeds to 
an individual assessment of lifestyle and biochemical param-
eters which may be predisposing to renal stone formation. 
Within medicine, it is often costly to ignore the opportunity 
for preventative intervention, both on an economic basis and 
in achieving good long-term patient outcomes. Accurately 
diagnosing the underlying cause of nephrolithiasis is cru-
cial from a prognostic and therapeutic point of view [7]. 
Common causes of calcium oxalate nephrolithiasis must be 
delineated from rare causes, as the latter often carry a poorer 
prognosis with significant risk of progression to end-stage 
renal failure [7]. Stone-forming conditions such as cystinu-
ria [24], primary hyperoxaluria [13] and adenine phospho-
ribosyltransferase (APRT) deficiency (producing 2,8-dihy-
droxyadenine stones) [26] are all also associated with risk 
of progression to end-stage renal disease, highlighting the 
crucial need for prompt diagnosis and preventative meas-
ures. The recently produced NICE guidance for renal and 
ureteric stones (https ://www.nice.org.uk/guida nce/indev 
elopm ent/gid-ng100 33) advocates stone analysis in adult 
patients with stones.
As extreme as it may sound, it is possible for a missed 
diagnosis of a monogenic stone-forming condition such as 
primary hyperoxaluria or APRT deficiency to have devastat-
ing consequences. Missing a diagnosis of primary hyperox-
aluria type 1 may lead to disease recurrence and oxalosis of 
a transplanted kidney [7], and the omission of the considera-
tion of a curative liver transplantation. Undetected APRT 
deficiency can sometimes lead to ESRD and is also associ-
ated with recurrence of stone disease in a renal transplant, 
leading to loss of graft function if untreated [2].
Making a diagnosis in such cases ultimately relies on a 
combination of modalities, including stone analysis, urine 
biochemistry and genetic investigations. Whilst used as 
extreme examples they should also point to the fact that pre-
cision medicine approaches to stone-formers are not purely 
genetic but utilise the breadth of phenotypic information 
available.
Promoting an individualised approach 
to stone‑formers
The role of 24-h urine collections has been discussed in 
detail previously [15] and also in the accompanying discus-
sion to this debate by Goldfarb. Whilst perceived to be a spe-
cialist and difficult to interpret test by the non-expert, a 24-h 
urine collection provides valuable and patient specific data 
allowing a precision medicine approach to be adopted [21]. 
An accurate assessment of urine volume over a 24-h time 
period is often very revealing, and distinct urinary biochemi-
cal profiles can lead to specific risk factors and diagnoses 
being made. It is our view that along with stone analysis, 
a 24-h urine collection, with all the caveats that it entails, 
pushes the patient towards a very much more individualised 
management pathway and based on its results also paves the 
way for genetic investigations to be considered.
A pragmatic view is that a genetic set of investigations is 
only likely to be requested if there is an unusual stone type, 
an unusual biochemical profile or a striking family history 
of renal stone disease or ESRD. Therefore, one could argue 
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that whilst 24-h urines may be impractical and sometimes 
uninformative, it gives the personalised diagnostic pathway 
momentum which will drive consideration of genetic inves-
tigations. A 24-h urine collection or a spot urine evalua-
tion for cystine (cystine/creatinine ratio) remains a valuable 
screening test in stone–forming patients, in order to identify 
cystinuria. Cystinuria patients may also be detected follow-
ing stone analysis and microscopic examination of the urine 
[10]. Cystinuria accounts for 6–8% of stones in paediatric 
populations and around 1% of stones in adults [10] hence 
it is an important diagnosis to make, as the susceptibility 
to stones is lifelong. Traditionally, cystinuria patients and 
carriers have been attempted to be distinguished by cystine 
concentrations [11]. However, there are at least two genes 
implicated in cystinuria, SLC3A1 labelled as type A and 
SLC7A9, labelled as type B. Inheritance patterns are mixed 
with autosomal recessive and dominant patterns with partial 
penetrance. It is possible to have digenic forms of the con-
dition, for example type AB where two heterozygous vari-
ants (one from each gene) combine [24]. Indeed, sequencing 
of SLC7A9 and SLC3A1 allows a precise determination of 
genotype (and may reveal complex genotypes such as AAB 
and ABB, etc.) and allows at risk family members to be 
identified [24].
We have previously discussed in detail the importance 
of documenting a family history in the nephrology clinic 
[18]. In addition to this, age of onset of renal stone dis-
ease is particularly revealing. Paediatric patients presenting 
with early-onset of stone disease should arouse suspicion 
of a genetic cause and the clinician is led to look for these. 
However, when assessing the adult patient presenting with 
nephrolithiasis, clinicians may place less emphasis on fam-
ily history, as they are not expecting an index presentation 
of a genetic disorder in this age group. However, a study 
using gene sequencing to analyse a cohort of 272 known 
stone-formers with no genetic diagnosis at the time, demon-
strated that almost one-third of SLC7A9 mutations (causing 
type B cystinuria) had an age of stone onset between 18 
and 30 years, with a median age of 26 years [12]. There-
fore, it is crucial to elicit a careful family history, and also 
look for any clues such as extra-renal manifestations (sen-
sorineural hearing loss, neurological disorders) which may 
point towards a unifying underlying genetic disorder [7]. 
Other factors in the history, such as severity of disease or 
associated features such as nephrocalcinosis may also alert 
the clinician to search for a genetic cause [7]. Due to the 
varied clinical presentation and course of nephrolithiasis, 
absence of family history cannot be exclusively relied upon 
to exclude an underlying genetic cause; the clinician must 
remain vigilant to spot cases in which genetic testing may 
solve the diagnosis at an early stage and facilitate precise, 
individualised treatments.
Renal stones have a high frequency of recurrence. Bio-
chemical profiles and stone-composition analysis can be 
helpful tools in establishing an etiological diagnosis for the 
patient. However, analysis of a single renal stone gives a 
single point-in-time reference and may be misleading. For 
example, some patients with cystinuria have been found to 
form calcium oxalate stones (as their presenting stone event) 
prior to the formation/identification of cysteine stones [25]. 
Therefore, analysis of a single stone, which on that occasion 
was a calcium-based stone, could lead to a false conclusion 
that this was a patient with common calcium nephrolithiasis, 
missing the underlying genetic cause and hence the oppor-
tunity to appropriately tailor their treatment.
Precision medicine thus relies on using targeted investi-
gations at the right time for the right patient. Patients with 
an early age of renal stone onset are more likely to have an 
underlying monogenetic cause, and therefore genome-wide 
approaches such as whole exome sequencing (WES) may be 
an efficient method of determining the underlying diagnosis 
in patients presenting before the age of 25 [6]. The advan-
tage of WES over gene-panel sequencing is that more genes 
than the already ‘known’ nephrolithiasis genes can be tested, 
allowing detection of novel candidate genes [3].
Genetic cases of renal stone diseases: should 
you treat them differently?
Achieving a precise diagnosis of the underlying predispo-
sition to nephrolithiasis is crucial when it comes to treat-
ment options. Whilst generic treatment strategies such as 
maintaining adequate hydration might reduce stone burden 
in all stone-formers, this is a basic approach that neglects 
targeted therapies we know would be more successful in 
specific stone aetiologies.
For example, a low-salt diet may be generally helpful, 
but in cystinuria patients the priority should be to encourage 
a vegetarian or vegan diet (low in animal protein), aiming 
for an alkaline urine which reduces the likelihood of cys-
tine stone formation. An alternative non-dietary method of 
achieving urinary alkalinisation is through potassium citrate 
supplementation. Patients can be educated about monitoring 
their urine pH, empowering them to lead on their individual-
ised treatment plan. For patients with adenine phosphoribo-
syltransferase (APRT) deficiency, allopurinol is an effective 
treatment alongside generic fluid and dietary advice. These 
niche, inexpensive, simple treatments will only be initiated 
if the correct diagnosis has been made.
Reducing stone burden is crucial; whether you are try-
ing to escape excruciating renal colic pain, or avoid surgi-
cal interventions or long-term renal damage, every stone 
is significant. Precise treatment, of a known monogenic 
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cause (some examples are shown in Table 1), is preferable 
to empirical treatment which may well not be targeting the 
underlying problem. A detailed review of how these mono-
genic disorders provide opportunities for specific interven-
tions has recently been published [23].
Genetic investigations and gene discovery
With the growing ease and decreasing cost of genetic 
investigations it is notable that mutations in over 30 genes 
have been described in association with nephrolithiasis. 
Using next-generation sequencing approaches mutations 
were recently identified in SLC26A1 in patients with cal-
cium oxalate stones [8]. For SLC26A1 mutations, it is not 
yet clear what the exact underlying pathophysiological 
mechanisms are, but this example serves as a reminder 
that aside from the known causes of nephronophthisis, oth-
ers yet remain to be discovered. Indeed, recent descrip-
tions of stone formation in patients with Pseudoxanthoma 
elasticum (secondary to mutations in ABCC6) points us 
towards new ways of modelling and understanding renal 
stone formation [16], and perhaps a rediscovery of previ-
ously postulated precision therapies, including pyrophos-
phate [19, 20].
Inherited renal stone disease: it is all 
about being precise
Whilst renal stones can cause severe pain to the individual, 
on a population level only up to 10% of individuals are 
affected, and monogenetic cases of renal stone disease are 
even rarer [12]. However, making an early precise diag-
nosis of renal stone aetiology has a huge impact for the 
individual (and often other family members), allowing 
their treatment to be individualised and aiming to mini-
mise any risk of progression to end-stage renal disease. 
Molecular genetic testing is becoming more accessible in a 
clinical rather than research context, and should be utilised 
where necessary to facilitate a precise diagnosis for the 
patient and their family. As clinicians we should aspire to 
maximise preventative interventions, appropriately using 
patient history, family history and clinical features such 
as extra-renal manifestations to identify cases which may 
be typical of monogenic disease. 24-h urine profiles when 
performed, will add to the diagnostic pathway and may 
reveal unexpected findings. Together these approaches 
should point the clinician towards genetic testing which 
may reveal vital diagnostic information. The priority 
should be to think ahead, trying to also target the disease 
process rather than react secondarily to stone burden, and 
tailoring the approach to the individual patient.
The influence of the microbiome and stone 
disease
Microorganisms which colonise the human body are 
known collectively as the microbiome. In relatively recent 
studies, we are beginning to understand the importance of 
the role of the microbiome and how it communicates and 
influences the human body. Specifically the gut microbi-
ome may influence the absorption and secretion of com-
pounds implicated in renal stone formation. Distinct dif-
ferences have been observed in the microbiome of renal 
stone-formers when compared to healthy controls [30, 
31]. The identification of Oxalobactor formigenes [1], 
a bacteria which promotes the breakdown of oxalate in 
the gut, led to clinical trials using manipulation of the 
gut flora with dosing of O. formigenes [14]. These studies 
have led to more in-depth considerations of how an indi-
vidual stone-former may be influenced by their own gut 
microbiome and directing therapies (such as pro-biotics) to 
manipulate this must be part of future precision medicine 
discussions for renal stone-formers.
Conclusion
Renal stone disease is a huge burden on world health sys-
tems and any efforts directed at identifying an underlying 
and reversible cause should be undertaken. We advocate 
using a precision medicine approach to every stone-former 
which must include careful phenotyping, including stone 
analysis and 24-h urine collection, the results of which may 
prompt genetic testing. Empiric advice whilst welcome does 
not go far enough to target many of the known pathophysi-
ological mechanisms of stone formation.
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